Two U.K. health ministers are calling on Vertex Pharmaceuticals (VRTX) to provide an “urgent resolution” to negotiations over access to its cystic fibrosis drug, a battle that has lingered for two years and caused a ruckus among patients and government officials.
The company should “commit to pricing that is responsible and proportionate to the benefits that patients receive,” and provide “all available data supporting the cost effectiveness” of its most recent proposal to the government, according to an April 19 letter from Steve Brine, the under secretary of state for public health and primary care, and Lord O’Shaughnessy, the under secretary of state for health. A Vertex spokeswoman wrote us to say that a meeting with the National Health Service is scheduled for this week.
About the Author Reprints
Why no annual price info? Even a range would be helpful